Abstract
Enrollment for the study was from February 2016 to December 2017. The MIBO guidelines were published in 2017, 1 when enrollment was near complete. Ideal accommodations to appropriately quantify the platelet-rich plasma and cBMA products for the remaining subjects in this study were sought after MIBO was published but were not attained. Practical accommodations were adopted based on financial constraints and outsourcing availability.
In 2018, Andrews Research and Education Foundation acquired the in-house capabilities to quantify biologic products moving forward, including automated and manual methods. The bone marrow aspirate technique used in this study is similar to that published by Oliver et al, 2 with the exception of 30-mL syringes.
Footnotes
One or more of the authors has declared the following potential conflict of interest or source of funding: A.W.A. has received consulting fees from Arthrex; speaking fees from Arthrex, Smith & Nephew, and Ossur; and royalties from Arthrex. J.G.H. has received honoraria from Avanos Medical, Fidia Pharma, and Tenex Health and consulting fees from Ferring Pharmaceuticals and Fujifilm SonoSite. AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.